Fresenius Medical Care

FMS

Capitalización de mercado USD 11.8 mil M

FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.

FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.

Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in related one-time costs in Q3 2026 treated as a special item BAD HOMBURG, Germany, Sept. 25, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced refinements to its China commercial strategy to support long-term growth and strengthen its market position through a more localized portfolio, increased commercialization of locally relevant innovation and a focused go-to-market approach.

Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.

These stocks have economic moats and look attractive today.

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half.

Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.